Novavax Non Currrent Assets Other from 2010 to 2024

NVAX Stock  USD 8.47  0.43  5.35%   
Novavax Non Currrent Assets Other yearly trend continues to be fairly stable with very little volatility. Non Currrent Assets Other are likely to outpace its year average in 2024. Non Currrent Assets Other is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. View All Fundamentals
 
Non Currrent Assets Other  
First Reported
1996-03-31
Previous Quarter
28.9 M
Current Value
30.5 M
Quarterly Volatility
12.4 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Novavax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novavax's main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.3 M, Interest Expense of 15.1 M or Selling General Administrative of 499.1 M, as well as many indicators such as Price To Sales Ratio of 0.47, Dividend Yield of 0.0066 or Days Sales Outstanding of 82.31. Novavax financial statements analysis is a perfect complement when working with Novavax Valuation or Volatility modules.
  
Check out the analysis of Novavax Correlation against competitors.
For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Latest Novavax's Non Currrent Assets Other Growth Pattern

Below is the plot of the Non Currrent Assets Other of Novavax over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. Novavax's Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novavax's overall financial position and show how it may be relating to other accounts over time.
Non Currrent Assets Other10 Years Trend
Slightly volatile
   Non Currrent Assets Other   
       Timeline  

Novavax Non Currrent Assets Other Regression Statistics

Arithmetic Mean20,198,633
Geometric Mean5,065,599
Coefficient Of Variation159.40
Mean Deviation24,670,662
Median2,581,000
Standard Deviation32,196,908
Sample Variance1036.6T
Range92.1M
R-Value0.78
Mean Square Error442.4T
R-Squared0.60
Significance0.0007
Slope5,593,930
Total Sum of Squares14513T

Novavax Non Currrent Assets Other History

202492.5 M
202388.1 M
202228.5 M
202156.7 M
202013.2 M
20197.5 M
20181.8 M

About Novavax Financial Statements

Novavax investors use historical fundamental indicators, such as Novavax's Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Novavax. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Currrent Assets Other88.1 M92.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Novavax Stock Analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.